This content is from: Premium
Hedge Funds Surface in Wave of Biopharma SPAC Deals
RTW and Perceptive Advisors are among investors seen in recent SPAC deals in biopharma.
The rise of special purpose acquisition companies is giving investors in private companies a public avenue to exit their deals.SPACs, or blank check companies designed to buy businesses and instantly take them public, tend to be less expensive and faster than initial public offerings. Many companies targeted by SPACs are backed
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.